Based on a new study of the safety and abuse potential of psilocybin, the hallucinogenic drug in magic mushrooms, Johns Hopkins University School of Medicine researchers recommend that "psilocybin should be re-categorized from a schedule I drug—one with no known medical potential—to a schedule IV drug such as prescription sleep aids, but with tighter control."
Read the rest
Greg Miller writes that the study of psychedelics has recovered after "Timothy Leary really screwed things up for science", and is emerging from dormancy.
“The antics of Timothy Leary really undermined the scientific approach to studying these compounds,” psychopharmacologist Roland Griffiths of Johns Hopkins University told the audience. But the times they are a-changin’. In recent years, a small cadre of scientists has cautiously rekindled the scientific study of psychedelics. At the conference, they reported new findings on how these drugs scramble brain activity in ways that might help explain their mind-bending effects. They’re also slowly building a case that these drugs might help people with depression, anxiety and other disorders.
Translation: drug companies need new products, badly.
Photo: Shutterstock Read the rest